

28. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition comprises an admixture of ~~mycobacterium~~ Mycobacterium w and constituents of mycobacterium w prepared by cell disruption.

29. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition comprises constituents of ~~mycobacterium~~ Mycobacterium w prepared by cell disruption.

30. (Currently Amended) The method of claim 28, wherein the constituents of ~~mycobacterium~~ Mycobacterium w are prepared by sonication or high pressure fractionometer.

31. (Currently Amended) The method of claim 29, wherein the constituents of ~~mycobacterium~~ Mycobacterium w are prepared by sonication or high pressure fractionometer.

32. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition comprises constituents of ~~mycobacterium~~ Mycobacterium w prepared by solvent extraction.

33. (Previously Presented) The method of claim 32, wherein the solvent is selected from the group consisting of chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea and hexane.

34. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition comprises constituents of ~~mycobacterium~~ Mycobacterium w prepared by enzymatic extraction.

35. (Previously Presented) The method of claim 34, wherein the enzymatic extraction is carried out using lyticase and/or pronase.

36. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises an adjuvant.

37. (Previously Presented) The method of claim 36, wherein the adjuvant is selected from mineral oil, mineral oil and surfactant, Ribi adjuvant, Titer-max, syntax adjuvant formulation, aluminum salt adjuvant, nitrocellulose adsorbed antigen, immune stimulating complexes, Gebru adjuvant, super carrier, elvax 40w, L-tyrosine, monatanide (manide – oleate compound), Adju prime, Squalene, Sodium phthalyl lipopoly saccharide, calcium phosphate, saponin, melanoma antigen and muramyl dipeptide (MDP).

38. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises a surfactant.

39. (Previously Presented) The method of claim 38, wherein the surfactant is polyoxyethylene sorbitan monooleate (Tween 80) or Triton X100.

40. (Previously Presented) The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.4%.

41. (Previously Presented) The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.1%.

42. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises a preservative.

43. (Previously Presented) The method of claim 42, wherein the preservative is Thiomerosal and is present in a concentration of 0.01% w/v.

44. (Currently Amended) The method of claim 22, wherein the ~~mycobacterium~~ Mycobacterium w is dead ~~mycobacterium~~ mycobacterium w.

45. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least 10^5 ~~mycobacterium~~ Mycobacterium w.

46. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least 10^7 ~~mycobacterium~~ Mycobacterium w.

47. (Currently Amended) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising between 10^8 and 10^9 ~~mycobacterium~~ Mycobacterium w.

48. (New) The method of claim 22, wherein the constituent of Mycobacterium w is prepared by cell disruption, solvent extraction, or enzymatic extraction.